News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genetic Immunity Clinical Trial Data Published in PLoS ONE


5/17/2012 9:44:46 AM

MCLEAN, Va. and BUDAPEST, Hungary, May 17, 2012 (GLOBE NEWSWIRE) -- Genetic Immunity Inc., a privately-held, biopharmaceutical company developing Langerhans cell-targeted immunotherapies, published its human proof-of-concept clinical trial, in PLoS ONE, a highly-regarded medical industry publication. The data demonstrated the induction of long-lasting memory T cell responses after a single immunization of DermaVir, the Company's lead vaccine candidate for patients infected with the human immunodeficiency virus (HIV). The publication is free to access in www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0035416.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES